NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Group suing over Pfizer diversity fellowship program loses US appeal

Published 03/06/2024, 12:07 PM
Updated 03/06/2024, 07:45 PM
© Reuters. FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
PFE
-

By Nate Raymond

(Reuters) -A U.S. appeals court on Wednesday upheld the dismissal of a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer (NYSE:PFE) fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker.

The New York-based 2nd U.S. Circuit Court of Appeals ruled the Virginia-based non-profit organization Do No Harm lacked standing to challenge the drugmaker's program, saying "it did not identify by name a single member injured by Pfizer's alleged discrimination."

Pfizer in a statement welcomed the ruling, saying it was an "equal opportunity employer and is proud of its commitment to diversity, equity and inclusion."

Do No Harm in a statement said it would seek further appellate review of the court's decision, "which departs from established precedent and makes it unduly hard for organizations to vindicate civil rights."

The group said it counts doctors, medical students and others as members and aims "to protect healthcare from radical, divisive and discriminatory ideologies."

Do No Harm sued Pfizer in 2022 over the company's Breakthrough Fellowship Program, which aimed to increase the pipeline of Black, Latino and Native American leaders, arguing it discriminated against white and Asian-American applicants.

Pfizer altered the program's criteria while the case was pending and now anyone can apply.

The lawsuit was filed a month before the U.S. Supreme Court heard arguments in cases in which its conservative majority would later in June 2023 declare unlawful race-conscious college admissions policies used by Harvard University and the University of North Carolina.

That decision, while focused on college admissions, has prompted a wave of lawsuits challenging diversity programs at companies, some of which have since altered their policies.

The lawsuit against Pfizer claimed its program violated laws including Section 1981 of the Civil Rights Act of 1866, which bars racial bias in contracting, and Title VI of the Civil Rights Act of 1964, which protects employees and job applicants from racial discrimination.

In Wednesday's opinion, U.S. Circuit Judge Beth Robinson said Do No Harm claimed to have standing to challenge the program because two anonymous white or Asian-American members of the group claimed they could not apply to the fellowship.

But Robinson, an appointee of Democratic President Joe Biden, said Do No Harm never disclosed the identities of either member to the court and that as a result a lower court judge rightly concluded it failed to establish standing.

© Reuters. FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Two other 2nd Circuit judges agreed to affirm the case's dismissal. One of them, U.S. Circuit Judge Richard Wesley, an appointee of Republican former President George W. Bush, only partially concurred, saying the two other judges went too far by imposing a rule requiring associations to name their members to prove standing.

"That is an unfortunate ruling for organizations everywhere," Wesley wrote.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.